Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON-SEOM registry.

However, the result was borderline significant ( p = 0.073) [ 36 ].

also in 5,455 other papers

In contemporary trials, there's a notable trend of equating all platinum and fluoropyrimidine doublets under the assumption that any differences between existing options are thought to be minimal.

also in 2,062 other papers